1. Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. The scope of the Study
2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.3. Analytics Tools & Model
2.4. Economic Indicators
2.4.1.Base Year, Base Currency & Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
3. Market Analysis
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1 Bargaining Power of Suppliers
3.2.2 Bargaining Power of Buyers
3.2.3 Threat of Substitutes
3.2.4 Threat of New Entrants
3.2.5 Industry Rivalry (Competitive Environment)
3.3. PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4. SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.4.5 Y-O-Y Analysis
4. Market Dynamics
4.1. Drivers
4.1.1 Increase in corporate partnerships to accelerate development and commercialise of regenerative medicine.
4.1.2 Increase in global healthcare expenditure.
4.1.3 Rapid growth in ageing population.
4.1.4. Prevalence of chronic diseases and genetic disorders.
4.2. Restraints
4.2.1 Cost of treatment.
4.2.2 Complex regeneration process.
4.2.3. Lack of guidelines.
4.2.4. Ethical concerns with the use of embryonic stem cell for research and development.
4.3. Opportunities
4.3.1. Strong product pipeline.
4.3.2. The great demand for organ transplantation.
4.4. Challenges
4.4.1 Stringent regulatory policies about stem cell technologies.
5. The Middle East and Africa Cancer Biomarkers Market – By Disease
5.1 Introduction
5.2 Prostate cancer
5.3 Lung cancer
5.4 Cervical cancer
5.5 Colorectal cancer
5.6 Breast cancer
6. The Middle East and Africa Cancer Biomarkers Market - By Application
6.1 Introduction
6.2 Risk assessment
6.3 Disease diagnostics
6.4 Development of molecular diagnostics
6.5 Drug formation
7. The Middle East and Africa Cancer Biomarkers Market – By Service
7.1 Introduction
7.2 Sample preparation
7.3 Assay development
7.4 Biomarkers validation and testing
8. The Middle East and Africa Cancer Biomarkers Market – By Type
8.1 Introduction
8.2 Protein biomarkers
8.3 Cell biomarkers
8.4 Genetic biomarkers
8.5 Carbohydrate biomarkers
8.6 Viral biomarkers
8.7 Others
9. Middle East and Africa Cancer Biomarkers Market – By Technology
9.1 Introduction
9.2 Omics technology
9.3 Cytogenetics
9.4 Imaging technologies
9.5 Immuno Assays
9.6 Bioinformatics
9.7 IVD multivariate
9.8 Index assays
10. Middle East and Africa Cancer Biomarkers Market – By Country
10.1 The Middle East and Africa
10.1.1 Introduction
10.1.2 Saudi Arabia
10.1.3 Israel
10.1.4 UAE
10.1.5 Others
11. The Middle East and Africa Cancer Biomarkers Market - Company Profiles
11.1 Affymetrix Inc
11.2 Agendia BV
11.3 Abbott Laboratories
11.4 Roche Diagnostics Corp.
11.5 Agilent Technologies
11.6 Astex Pharmaceuticals
11.7 Illumina Inc
11.8 Diadexus Inc
11.9 Qiagen N.V
11.10 Aureon Biosciences Inc
11.11 Becton, Dickinson and Company
11.12 Beckman Coulter Inc
11.13 Clarient Inc
11.14 Astellas Pharma US Inc
12. The Middle East and Africa Cancer Biomarkers Market - Competitive Landscape
12.1 Market Share Analysis
12.2 Strategies Adopted by top companies
12.3 Merges, Acquisitions, Collaborations & Agreements
13. Market Insights
13.1 Industry Experts Insights
13.2 Analysts Opinions
13.3 Investment Opportunities
14. Appendix
14.1 List of tables
14.2 List of figures
